Korean botulinum toxins
Journal of Neural Transmission · 2026-06 · 133 (6) · 971-975
DOI: 10.1007/s00702-025-03076-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 31.01.2026. Verfasst von Dirk Dressler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. dressler.dirk@mh-hanno…. Hauptthemen laut MEDLINE: Botulinum Toxins, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Botulinum toxin (BT) is used therapeutically since the late 1980s. For many years, BT drugs were provided by a small group of manufacturers from Europe and the United States. As BT’s use for aesthetic purposes surged, numerous new manufacturers entered the field, particularly from Korea. We want to give an overview about the rapidly expanding and diversifying BT landscape in Korea. Altogether, there are 15 Korean manufacturers of 19 BT drugs registered in Korea, mainly for aesthetic indications. There are 2 Class 1 drugs from 2 Korean manufacturers registered in Korea for export, domestic use and registered in the USA and Europe. These are PrabotulinumtoxinA (Daewoong/Evolus) and LetibotulinumtoxinA (Hugel/Croma Pharma). There are 12 Class 2 drugs from 10 Korean manufacturers registered in Korea for export and domestic use, including Neuronox ® , the first Korean BT drug registered in 2006, NivobotulinumtoxinA/Innotox ® , the world-wide first liquid BT type A preparation and Coretox ® , the world-wide second BT drug without complexing proteins. Innotox ® and Toxsta ® are currently performing clinical studies in the USA. Additionally, there are 5 Class 3 BT drugs from 5 Korean manufacturers registered in Korea for export use only. 5 Korean manufacturers have 5 drug projects in Korea in advanced development phases. With this, Korea is now the country with the worldwide largest number of BT manufacturers and BT drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. dressler.dirk@mh-hannover.de.
- Botulinum Toxin Research Center, Tongji University Medical School, Shanghai, China. dressler.dirk@mh-hannover.de.
- Stellar-B, Seoul, Republic of Korea.
- Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA.
- IAB - Interdisciplinary Working Group for Movement Disorders, Hamburg, Germany.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Dressler, D., Kim, N., Johnson, E. A., & Adib Saberi, F. (2026). Korean botulinum toxins. Journal of Neural Transmission, 133(6), 971-975. https://doi.org/10.1007/s00702-025-03076-x
Vancouver
Dressler D, Kim N, Johnson EA, Adib Saberi F. Korean botulinum toxins. Journal of Neural Transmission. 2026;133(6):971-975. doi:10.1007/s00702-025-03076-x
BibTeX
@article{Dressler2026,
author = {Dressler, Dirk and Kim, Nayoung and Johnson, Eric A and Adib Saberi, Fereshte},
title = {Korean botulinum toxins},
journal = {Journal of Neural Transmission},
year = {2026},
volume = {133},
number = {6},
pages = {971--975},
doi = {10.1007/s00702-025-03076-x}
}
EUVIMED